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Accepted 8 April 2013AbstractObjectives: Discuss the tradeoffs inherent in choosing a local area size when using a measure of local area practice style as an instru-
ment in instrumental variable estimation when assessing treatment effectiveness.
Study Design: Assess the effectiveness of angiotensin converting-enzyme inhibitors and angiotensin receptor blockers on survival after
acute myocardial infarction for Medicare beneficiaries using practice style instruments based on different-sized local areas around patients.
We contrasted treatment effect estimates using different local area sizes in terms of the strength of the relationship between local area prac-
tice styles and individual patient treatment choices; and indirect assessments of the assumption violations.
Results: Using smaller local areas to measure practice styles exploits more treatment variation and results in smaller standard errors.
However, if treatment effects are heterogeneous, the use of smaller local areas may increase the risk that local practice style measures are
dominated by differences in average treatment effectiveness across areas and bias results toward greater effectiveness.
Conclusion: Local area practice style measures can be useful instruments in instrumental variable analysis, but the use of smaller local
area sizes to generate greater treatment variation may result in treatment effect estimates that are biased toward higher effectiveness. As-
sessment of whether ecological bias can be mitigated by changing local area size requires the use of outside data sources.  2013 Elsevier
Inc. All rights reserved.
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Instrumental variable (IV) estimators have been recog-
nized as useful tools to assess the effectiveness of alternative
treatments in health care using observational data [1,2]. The
‘‘instruments’’ required in IV studies must be measured fac-
tors that are strongly related to treatment choice but are unre-
lated to either study outcomes or other unmeasured factors
related to study outcomes. Thus, instruments essentially pro-
vide an ex post randomization of treatment choice or expo-
sure across patients [3e9]. IV methods yield estimates of
the average treatment effect for the subset of patients whose
treatment choices were mutable to changes in the instrument
variable or ‘‘instrument’’ values [4,10e13]. IV estimatesConflict of interest: The authors have no conflicts of interest related to
the content of this article.
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http://dx.doi.org/10.1016/j.jclinepi.2013.04.008have been labeled a local average treatment effect (LATE)
and are thought to be most suitable to assess the effect of
treatment rate changes in a population [7,8,10e14].Many re-
searchers have used local area practice style measures as in-
struments in IV analysis [15e28], which conjectures that
patients residing in areas where physicians have stronger
preferences for a particular treatment are more apt to receive
that treatment and unmeasured confounding variables are un-
related to the differential patient access to physicians with
distinct treatment preferences.
Only two studies that used a local area practice style
measure as instruments have reported whether their esti-
mates were robust to adjustments in the size of the local
area used to measure practice style [23,28], and there has
been no discussion as to the potential effects of local area
size on the properties of the resulting IVestimates. The size
of the local area used to measure practice style may affect
both the strength of the relationship between the instrument
and treatment choice and whether the instrument is related
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Key findings
 The use of smaller local areas to measure practice
styles as instruments exploits more treatment varia-
tion and results in smaller standard errors. However,
if treatment effects are heterogeneous, the use of
smaller local areas may increase the risk that local
practice style measures are dominated by idiosyn-
cratic differences in average treatment effectiveness
across areas resulting in treatment effect estimates
that are biased toward greater effectiveness.
What this adds to what was known?
 Local area practice style measures can be useful in-
struments in instrumental variable analysis, but the
use of smaller local area sizes to generate greater
treatment variation may result in treatment effect es-
timates that are biased toward higher effectiveness.
Assessment of whether ecological bias can be miti-
gated by changing local area size requires the use of
outside data sources.
What is the implication and what should change
now?
 Researchers should be aware that if treatment ef-
fects are heterogeneous across patients, the use of
small-sized local areas as the basis to measure lo-
cal practice style as an instrument may result in
treatment effect estimates that are biased in favor
of treatment.
to unmeasured confounding factors. One might expect that
the larger the local area around a patient residence used to
measure practice style the weaker the relationship will be
between the instrument and the treatment choices for indi-
vidual patients. Confounding emerges when local area
practice style measures are correlated with differences in
average unmeasured patient characteristics or ecological
factors across areas that are related to patient outcomes.
A priori relationships between local area size patient and
ecological factors that may confound estimates do not gen-
erally exist. Ecological factors have been categorized as ag-
gregate attributes (e.g., smoking rates, average health
behaviors), contagion factors (e.g., flu prevalence), environ-
mental factors (e.g., pollution, weather, sunlight hours);
patterns of interaction among area individuals (e.g., social
networks); and global factors (e.g., local regulations or
market structures) [29]. One can envision that smaller local
area sizes could introduce correlations between practice
style and unmeasured neighborhood-level cultural and
health behaviorerelated confounders. In contrast, use of
larger local area sizes may introduce correlations withregional unmeasured confounders related to regulatory
structures, regional health care systems, and climate. In ad-
dition, if the relationships between individual treatment
choice and local area practice style measures weaken as lo-
cal area size increases, this increases the potential for un-
measured patient and ecological factors to confound the
treatment effect estimates. However, the only possible ap-
proach to validate assumptions of no correlation between
local area practice style measures and confounding factors
for specific area sizes and is to obtain secondary data sour-
ces describing these factors and directly estimate the corre-
lations by area size.
If treatment effectiveness is heterogeneous across pa-
tients, another source of confounding related to local area
size needs to be considered. ‘‘Essential heterogeneity’’ oc-
curs when treatment effects are heterogeneous across pa-
tients and providers make treatment recommendations
based on patient characteristics that are related to expected
treatment effectiveness [19,21,30e32]. If the patient char-
acteristics related to treatment effectiveness are unobserved
by the researcher, we theorize that local area practice style
measures will be positively correlated with average treat-
ment effectiveness across areas causing LATE estimates
to be biased toward positive treatment effectiveness. It will
appear that higher treatment rates will yield better out-
comes when in fact areas with higher treatment rates simply
contained more patients apt to gain from treatment. How-
ever, as we discuss in Appendix A, as the number of pa-
tients used to define a local area increases, the favorable
bias in LATE estimates from this effect will diminish.
The objective of this study is to discuss the tradeoffs in-
volved in choosing a local area size when using local area
practice style as an instrument. We used IV methods to es-
timate the LATE of renineangiotensin system antagonists
including angiotensin converting enzyme (ACE) inhibitors
and angiotensin receptor blockers (ARBs) on 1-year patient
survival among Medicare patients after acute myocardial
infarction (AMI). ACE/ARB use post-AMI provides an in-
teresting setting for this discussion because the benefits of
ACE/ARBs are known to be heterogeneous across AMI pa-
tients with greater benefit for patients at higher risk of fu-
ture cardiovascular events [33]. ACE/ARB survival
benefit estimates from randomized controlled trials (RCTs)
vary from 50 lives saved per 1,000 high-risk patients to 5
lives saved per 1,000 low-risk patients [34]. In addition, ev-
idence shows substantial variation in ACE/ARB prescribing
as only 50% of Medicare patients from two states received
an ACE/ARB post-AMI in 2004 [35], and large geographic
variation has been reported [36]. If providers believe ACE/
ARB benefits are heterogeneous across patients and ACE/
ARB treatments are sorted across AMI patients based on
expected benefitsd‘‘essential heterogeneity’’ [19,37]dwe
expect that local area ACE/ARB practice styles variation
will reflect moderate-risk AMI patients whose ACE/ARB
choices are more discretionary than either high- or low-
risk patients. As a result, IV estimates of LATE for ACE/
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fall between the RCT estimates described previously.
In addition, all else equal, if essential heterogeneity is oc-
curring we expect that LATE estimates will be biased high
and that the bias will diminish as the size of the local area
increases (see Appendix A). The consistency of our esti-
mates is also conditional on the assumptions that local area
ACE/ARB practice styles are unrelated to unmeasured av-
erage patient and ecological factors that affect cardiovascu-
lar patient outcomes, such as general provider access
[38,39], characteristics of the health care delivery system
[38,39], area socioeconomic status and homogeneity
[38e44], pollution [45], social environment and support
[39,46,47], and area health behaviors and disease preven-
tion [47].
We used the driving area for clinical care (DACC)
method to define local areas around Medicare AMI patient
residence ZIP codes [23,25,28]. The DACC method enables
researchers to create local area practice style measures for
alternative size definitions based on threshold numbers of
patients living within a specified driving time of each ZIP
code. Defining local areas based on the number of patients
instead of distances alone helps account for urban/rural dif-
ferences in health care access as rural patients routinely
drive greater distances for health care. Across local area
size definitions, we contrasted ACE/ARB 1-year survival
effectiveness estimates in terms of the strength of the rela-
tionship between local area practice styles and individual
patient treatment choices as well as indirect assessments
of the assumption of no correlation between local area prac-
tice style and unmeasured confounders.2. Methods
2.1. Data and sample
All Medicare claims files, enrollment information, and
part D prescription drug events for patients hospitalized
for their first AMI in 2008 who did not have AMI in
2006 and 2007 were obtained. We applied the Chronic Care
Warehouse definition of AMI as an inpatient stay with an
International Classification of Diseases, Ninth Revision
code 410.xx (excluding 410.x2) in the first or second diag-
nosis position of the claim [48]. AMI stay admission and
discharge dates were based on all Medicare institutional
claims (acute, long-term care hospital, inpatient rehabilita-
tion facility, critical-access hospital, and short-term nursing
facility) with overlapping admission and discharge dates af-
ter an initial acute hospital admission with an AMI diagno-
sis. We restricted our sample to patients discharged alive;
with continuous Medicare part A and B fee-for-service en-
rollment 12 months before their index AMI admission and
12 months after index discharge or until death; and with
continuous part D enrollment 6 months before admission
and 12 months after index discharge or until death. To en-
sure that all part D events were observable during a 30-daypostindex treatment observation period, we further ex-
cluded patients who used hospice or skilled nursing care;
were readmitted to inpatient care; or died within the 30-
day postindex discharge. Finally, because driving times
between ZIP codes may have inconsistent meaning for geo-
graphically noncontiguous areas, we restricted our sample
to patients living in the continental United States at AMI
admission. The final sample size was 68,236.2.2. Measures
Patients were designated as having been prescribed an
ACE/ARB post-AMI if they filled a prescription for an
ACE/ARB within 30 days post-AMI discharge (one if an
ACE/ARB prescription was filled within 30 days post-
AMI discharge, zero otherwise) [49]. The study outcome
was a binary variable equaling one if the patient survived
for 1 year after AMI discharge, zero otherwise. Measured
covariates included patient demographics; baseline medical
conditions for both the year before the AMI admission and
during the index AMI stay; medications used during the
180 days before the AMI admission; AMI diagnosis type
on admission; procedures during the AMI stay; complica-
tions during the AMI stay; other medications filled immedi-
ately after discharge (statins, beta blockers); part D variables
including premium levels and deductible phase at diagnosis;
whether patients were Medicaid dual eligible in their AMI
index month; and socioeconomic characteristics for the pa-
tient residence ZIP code (per capita income, poverty rate, ed-
ucation level, English-speaking percentage). Full definitions
of these variables are included in Appendix B.
We defined local area practice style as the average intent
of physicians in an area to prescribe ACE/ARBs for pa-
tients on AMI discharge. Because measurement of treat-
ment intent is less clear for patients already using ACE/
ARBs when admitted for an AMI, to measure intent we
used the patients who did not have ACE/ARBs available
at home on their index AMI admission date based on pre-
vious prescription dates and days supplied figures on part
D claims (N5 43,842). For these patients, we created a var-
iable equaling one if the patients filled an ACE/ARB pre-
scription within 1 day of their first prescription claim in
the first 30 days post-AMI discharge, zero otherwise. With
these patients and this treatment definition, we measured
local area ACE/ARB practice style at the patient ZIP code
level using the DACC method. This method creates ‘‘local
areas’’ around each patient residence ZIP code by consec-
utively adding patients from the next closest ZIP codes
based on driving times between ZIP codes until a threshold
number of patients is reached. Distinct local area sizes were
created by varying the threshold number of patients from
10 to 200 patients in increments of 10. For the patients as-
sociated by the DACC method with each ZIP code for an
area size definition, we calculated ZIP codeespecific area
treatment ratios (ATRs) as the ratio of the number of pa-
tients receiving ACE/ARBs after AMI over the sum of
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ACE/ARB probabilities were predicted using a multivariate
logistic model of ACE/ARB choice over the patients with
no ACE/ARBs available at index using the measured cova-
riates described previously as independent variables. Pa-
tients in our full sample (N 5 68,236) were then assigned
local practice style ATR values for each of the 20 area size
definitions based on their residence ZIP code.2.3. Analytical approach
We applied the linear two-stage least squares (2SLS) IV
estimator that has been used in several previous IV studies
[10,18,19,21,22,28]. Linear 2SLS yields consistent esti-
mates that are robust to underlying error distributions un-
like other estimators based on distributional assumptions
that yield inconsistent estimates if the assumptions are
wrong [50,51]. In the first stage of 2SLS, a linear probabil-
ity model of ACE/ARB choice was estimated for the
68,236 patients in our sample. Independent variables in
the first stage model were the measured covariates de-
scribed previously and the local area ACE/ARB practice
style instrument. The instrument was specified empirically
using nine binary variables that placed each patient resi-
dence ZIP code ATR within deciles of the distribution of
ATRs across patients. In the second stage of 2SLS, a linear
probability model of 1-year survival was estimated. The
second-stage model specified all the noninstrument covari-
ates from the first-stage model as independent variables
plus the predicted ACE/ARB choice probability from the
first stage. Using this approach, the estimated parameterTable 1. Statistics describing ZIP codes within local areas around patient re
area
Threshold number of patients in local area
Driving time in minutes r
patient threshold
Mean Minimum
10 26.5 0.0
20 34.2 0.0
30 39.9 0.0
40 44.5 4.5
50 48.5 4.9
60 52.1 4.9
70 55.4 5.3
80 58.5 5.3
90 61.3 6.4
100 64.2 6.4
110 67.0 6.5
120 69.6 7.1
130 72.1 7.1
140 74.5 7.8
150 76.7 7.8
160 78.9 8.1
170 81.2 8.9
180 83.3 8.9
190 85.4 9.5
200 87.5 9.9associated with the predicted ACE/ARB choice probability
in the second-stage model is the LATE. We repeated this
2SLS method using ACE/ARB ATR values across the 20
different local area sizes. For each local area size, we esti-
mated (1) the strength of the relationship between the in-
strument and ACE/ARB treatment choice via the Chow
[52] F-value that tests whether the local area practice style
instrument describes a statistically significant portion of the
variation in ACE/ARB choice; (2) the ACE/ARB 1-year
survival LATE estimate with respective standard error; (3)
the Hausman overidentification test statistic [53]; and (4)
the correlation between ACE/ARB ATR and overall life ex-
pectancy for the county containing each patient ZIP code
[54]. Statistics (3) and (4) provide indirect assessments of
whether the instruments are related to unmeasured con-
founding variables. The Hausman overidentification statis-
tic tests the null hypothesis that the direct exclusion of
the instrument from the second-stage 1-year survival equa-
tion was appropriate. A high Hausman statistic rejects the
null hypothesis, suggesting a relationship between the in-
strument and survival [53]. The correlation parameter be-
tween local area ACE/ARB practice style and local area
life expectancy suggests whether ACE/ARB practice styles
are related to unmeasured differences in baseline patient
health at diagnosis.3. Results
Table 1 describes the local areas defined using the
DACC method by the number of threshold patients used.sidence ZIP codes by the threshold number of patient defining a local
equired to reach
number
Number of ZIP codes required to reach
patient threshold number
Maximum Mean Minimum Maximum
384.6 12.1 1 234
384.6 22.6 1 262
384.6 33.0 1 274
384.6 43.4 2 288
384.6 53.5 2 303
384.6 63.7 2 321
384.6 73.8 3 341
384.6 83.7 4 353
423.1 93.7 5 369
423.1 103.7 5 377
423.1 113.8 5 417
423.1 123.8 6 427
423.1 133.7 7 443
423.1 143.6 7 453
423.1 153.2 7 467
423.1 162.8 8 475
433.7 172.4 9 495
433.7 182.0 9 506
510.4 191.7 9 520
510.4 201.2 9 532
Fig. 1. First-stage F statistics for the effect of local area practice style
on angiotensin converting enzyme/angiotensin receptor blocker use by
local area size (10e200 patients).
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minutes from each ZIP code and 12.1 ZIP codes to find suf-
ficient patients, whereas for the 200-person local areas itFig. 2. (A) Northeast US ACE/ARB area treatment ratios (ATRs) based on l
Northeast US ACE/ARB ATRs based on local areas defined using 200 patie
ARB, angiotensin receptor blocker.took an average of 87.5 driving minutes from each ZIP
code and 201.2 ZIP codes to find sufficient patients.
Fig. 1 shows the relationship between the first-stage model
Chow F statistics assessing the strength of the local area
practice style instrument and individual patient ACE/ARB
choice by local area size. All F statistics show statistically
significant relationships between local area ACE/ARB
practice styles and ACE/ARB choice, but the values of
the F statistics fell (from 232 to 28) as the local area size
increases. Fig. 2A and B presents maps of the northeastern
United States illustrating the dispersion of ATR values for
10-patient and 200-patient areas, respectively. These figures
show substantial geographic variation in the ACE/ARB use
regardless of the local area size, but more practice style var-
iation is revealed using the 10-patient sized local areas.
Table 2 contrasts ACE/ARB treatment rates, unadjusted
outcome rates, and selected measured covariate averages
between patients grouped by ACE/ARB treatment choice,
and the 1st and 10th deciles of the ACE/ARB ATR for
10-, 100-, and 200-patient defined local areas. We also re-
port CochraneArmitage trend tests for each measured char-
acteristic across the ATR deciles groups for each local areaocal areas defined using 10 patients around five-digit ZIP codes. (B)
nts around five-digit ZIP codes. ACE, angiotensin converting enzyme;
Table 2. Acute myocardial infarction patient characteristics by ACE/ARB choice and local area practice styles defined using different area sizes (10, 100, 200)
Selected measured covariates
ACE/ARB in 30 d
Local area practice style area size
10-Person local areas 100-Person local areas 200-Person local areas
No Yes P-value (c2) 1st decile 10th decile Trend testa 1st decile 10th decile Trend testa 1st decile 10th decile Trend testa
Number of patients 33,757 34,479 6,824 6,824 P-value 6,825 6,825 P-value 6,821 6,821 P-value
Column %
ACE/ARB Rx%b 0 100 !0.0001* 35.0 64.0 !0.0001* 42.8 57.1 !0.0001* 44.2 56.3 !0.0001*
1-yr survival % 81.7 87.6 !0.0001* 82.8 84.7 0.0054* 83.3 84.6 0.5427 83.8 84.3 0.4997
Age
66e75 35.6 41.6 !0.0001* 36.9 38.5 0.0482* 36.8 40.1 !0.0001* 36.4 38.8 0.0038*
76e85 39.5 39 0.2176 39.9 39.4 0.0507 40.6 37.3 !0.0001* 40.5 38.4 !0.0001*
85þ 24.9 19.4 !0.0001* 23.2 22.1 0.9851 22.5 22.6 0.5585 23.1 22.8 0.2538
Race
White 84.5 82.5 !0.0001* 84.8 82.6 0.0163* 86.2 81.8 !0.0001* 87.9 79.8 !0.0001*
Black 7.5 8.0 0.0296* 7.6 9.4 0.2996 7.6 10.1 !0.0001* 6.9 11.1 !0.0001*
Other 8.0 9.6 !0.0001* 7.6 8.0 0.0299* 6.2 8.1 !0.0001* 5.2 9.1 !0.0001*
Metroc 71.2 68.7 !0.0001* 70.2 70.3 0.7837 70.6 71.4 !0.0001* 69.2 70.2 !0.0001*
Low per capita incomed 48.3 50.8 !0.0001* 49.4 48.2 0.1770 49.1 49.7 !0.0001* 52.1 48.0 0.0012*
Charlson Scoreedpreindex
0 31.2 35.7 !0.0001* 31.7 32.8 0.1944 31.7 32.8 0.5323 32.7 33.0 0.7787
1 22.5 24.6 !0.0001* 23.3 23.1 0.5597 23.3 23.4 0.5941 23.9 23.2 0.7940
2 15.2 14.0 !0.0001* 16.2 14.8 0.0640 15.0 13.7 0.2998 14.8 14.8 0.5170
3 11.1 10.2 !0.0001* 11.1 10.7 0.8890 11.1 11.4 0.4147 10.9 11.0 0.1480
4þ 19.9 15.5 !0.0001* 17.8 18.6 0.5147 18.8 18.6 0.2869 17.6 17.9 0.9459
Anterior wall AMIf 4.9 8.2 !0.0001* 5.8 6.5 0.4406 5.9 6.5 0.3104 5.7 6.6 0.4593
NSTEMIg 78.7 72.8 !0.0001* 77.3 77.4 0.3574 77.8 76.7 0.4354 77.6 75.9 0.2170
ACE/ARB side effect
conditiondpreindexh
24.1 17.4 !0.0001* 21.6 21.4 0.1961 21.5 21.5 0.4023 20.6 21.2 0.9066
ACE/ARB side effect conditiondindexh 34.8 25.3 !0.0001* 31.9 30.3 0.0252* 30.9 30.9 0.3121 30.6 30.7 0.7472
Cardiac catheterization index 50.0 62.8 !0.0001* 55.4 55.9 0.7898 54.8 55.2 0.3402 56.2 55.7 0.5336
ACE use in 180 d preindex 28.2 43.1 !0.0001* 34.8 36.6 0.0201* 34.7 38.4 0.0005* 35.2 37.1 0.0165*
Abbreviations: ACE/ARB, angiotensin converting enzyme/angiotensin receptor blocker; AMI, angiotensin receptor blocker; NSTEMI, non-ST elevation myocardial infarction.
* P ! .05.
a CochraneArmitage test of trend in characteristic value across patients grouped into deciles based on local area ACE/ARB practice style measure. For example, the P-value metro tests
whether a linear trend in metro residence exists across the ACE/ARB practice styleebased patient groups.
b Percent of patients with an ACE/ARB prescription in 30 days after AMI discharge.
c Lived in a metropolitan area according to ruraleurban continuum codes developed by the United States Department of Agriculture Economic Research Service (http://www.ers.usda.gov/
topics/rural-economy-population/rural-classifications.aspx). Twenty patients had unknown metro size.
d Mean per capita income in ZIP code below ZIP code mean.
e Please refer [59].
f International Classification of Diseases, Ninth Revision (ICD-9) 410.0; 410.1.
g ICD-9 410.7.
h Patient had either angioedema (995.1); hyperkalemia (276.7); acute renal failure/acute tubular necrosis (584.xx); acute glomerulonephritis (580.xx); or chronic kidney disease (016.00,
016.01, 016.02, 016.03, 016.04, 016.05, 016.06, 095.4, 189.0, 189.9, 223.0, 236.91, 250.40, 250.41, 250.42, 250.43, 271.4, 274.1, 283.11, 403.01, 403.11, 403.91, 404.02,
404.03, 404.12, 404.13, 404.92, 404.93, 440.1, 442.1, 572.4, 582.xx, 583.xx, 585.xx, 586.xx, 588.xx, 591, 753.12, 753.13, 753.14, 753.15, 753.16, 753.17, 753.19, 753.20,
753.21, 753.22, 753.23, 753.29, 794.4).
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Fig. 4. Correlations of local area ACE/ARB area treatment ratio and lo-
cal area overall life expectancy by local area size (10e200 patients).
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an ACE/ARB prescription in the 30 days after AMI dis-
charge. Patients who received an ACE/ARB tended to be
younger; had fewer comorbidities before AMI admission;
had high-risk AMIs; were more likely to have had a cardiac
catheterization during their AMI admission; were less
likely to have conditions related to ACE/ARB side effects
either before or during admission; and were more likely
to have used an ACE/ARB before their index AMI. Group-
ing patients by the ACE/ARB ZIP code ATRs revealed
substantial ACE/ARB treatment variation across local
areas, but the extent of variation falls with the local area
size. For example, ACE/ARB treatment rates varied from
35.0% to 64.0% moving from the 1st to 10th decile with
the 10-patient local area size but varied only from 44.2%
to 56.3% using the 200-patient local area size. Compared
with grouping patients by ACE/ARB treatment, grouping
patients by ZIP code ATRs increased the balance in all
measured confounders except patient race. Fig. 3 presents
the Hausman overidentification statistics for the IV model
estimated for each local area size. The Hausman test statis-
tic ranged from 0.47 to 2.21, and all were statistically
insignificant except those estimated using the 60- and
100-person sized local areas. The Hausman test statistic
appears to trend downward as local area size increases.
Fig. 4 presents estimated correlations between local area
ACE/ARB practice style measures and local area overall
life expectancy across local area sizes. A small positive cor-
relation between ACE/ARB practice style and local area
life expectancy is observed that trends higher as local area
size increases.
Fig. 5 plots the LATE estimates and respective standard
errors by local area size. Estimates of LATE ranged from
0.003 to 0.041 (i.e., 41 additional patients per 1,000
treated survive for 1 year after AMI). Only the IV estimate
produced with the 10-person local area (0.041 or 41 pa-
tients per additional 1,000 treated survive 1 year) is statis-
tically different from zero. IV estimates trend downwardFig. 3. Overidentification F statistics by local area size (10e200
patients).moving from 10-person to 120-person local areas but trend
upward for local areas defined using greater than 120
persons.4. Discussion
IV methods yield LATE estimates that are representative
of the subset of patients whose treatment choices were re-
sponsive to the instrument specified in the analysis [13].
Methodologists have stressed that LATE estimates are best
applied to policy questions that are closely aligned with the
treatment variation generated by the instruments specified
[57]. As such, our LATE estimates of ACE/ARBs on
1-year survival post-AMI using local area practice styles
would be best used to address policy questions related to
whether changes in existing ACE/ARB rates will affect pa-
tient survival. For example, what survival benefits will be
gained by moving from a 50.5% ACE/ARB treatment rate
to a 55% rate, or what benefits would be lost from reducing
the ACE/ARB treatment rate to 45%? As has been argued,Fig. 5. Instrumental variable parameter estimates and standard errors
for the effect of angiotensin converting enzyme/angiotensin receptor
blocker prescribing post AMI on 1-year survival and standard error
by local area size (10e200 patients).
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these questions than estimates from RCTs [4,12,14,58].
We found that the ATR-based measures of local practice
style describe a statistically significant portion of variation
in ACE/ARB use across all local area sizes. All F statistics
across local area sizes were greater than 10, which is con-
sidered the threshold of ‘‘weak instruments’’ in the IV lit-
erature [18]. However, as seen in Fig. 1, as the local area
size expands, the strength of the relationship between local
area practice style measures and individual patient ACE/
ARB choice diminishes. A direct effect of this reduction
can be seen in the increase in the standard errors of the
ACE/ARB treatment effect estimates in Fig. 5. If the treat-
ment effect standard error found in the 10-patient local area
was maintained across local area sizes, six of the 20 treat-
ment effect estimates would have been statistically signifi-
cantly different from zero at the 0.05 level.
We discussed two main sources of bias for LATE esti-
mates using ATR-based measures of local area practice
styles in IV estimation. We theorized in Appendix A that
using ATR-based instruments will yield estimates of LATE
with a positive bias but that this bias will diminish as local
area size increases. It is also possible that for certain local
area sizes ATR-based measures could be correlated with ei-
ther average patient characteristics or ecological factors
that affect outcome directly. Previous studies have sug-
gested several potential confounding factors, but there are
no a priori relationships that would associate these factors
with ATR-based measures of local practice styles by local
area size. We suggest researchers should look for anomalies
in LATE estimates across local area sizes and search for
secondary sources of information to assess the validity of
estimates. We provide an example of this by estimating cor-
relations between local area ACE/ARB ATR values and lo-
cal area overall life expectancies. In future, research
medical charts from the index AMI could be abstracted
for a sample of patients in the highest and lowest ACE/
ARB ATR areas for several local area sizes to assess
whether average patient characteristics such as AMI sever-
ity varies with ATR values across local area sizes.
With respect to the effect of ACE/ARBs on 1-year sur-
vival post-AMI across local area sizes (Fig. 5), we found
that only the LATE estimate from the 10-person local area
size was statistically different from zero and that LATE es-
timates trended downward as local area size increased from
10 to 120 patients. This trend is consistent with the theory
we provide in Appendix A that ATR-based measures of lo-
cal area practice style will lead to LATE estimates with
positive bias but that this bias will diminish as local area
size increases. However, this trend clearly does not extend
to local area definitions greater than 120 patients as LATE
estimates trended upward for local area sizes using from
120 to 200 patients. The U-shaped relationship between
LATE estimates and local area size suggests that correla-
tions between local area size and unmeasured confounders
exist, but this U-shaped relationship alone is insufficient topinpoint which local area sizes have the most prominent
confounding problem. It is possible that correlations be-
tween unmeasured confounding factors and the ATR-
based instruments exist in the large-sized local areas that
bias LATE treatment effect estimates in a positive manner.
We did find small positive correlations between the ATR
values and life expectancy that get stronger as local area
size increases that support this notion. On the other hand,
it is possible that correlations between unmeasured con-
founding factors and the ATR-based instruments exist in
the small-sized local areas that bias treatment effects to-
ward zero (independent of the positive bias associated with
essential heterogeneity). The overidentification statistic es-
timates in Fig. 3 trend lower with increased local area size,
which provides some weight to this idea, but secondary
data sources are needed to further understand the source
of LATE estimate variation across area sizes.
Just more than 50% of the AMI patients in our sample
filled an ACE/ARB prescription in the 30 days after dis-
charge from their index AMI. If ACE/ARB prescribing is
sorted across AMI patients based on expected benefits (es-
sential heterogeneity) we expected that the treatment rate
variation identified by local area practice style differences
reflects treatment choices for patients whose expected treat-
ment benefits from ACE/ARBs are less definitive. As a re-
sult, we expected our estimates of the LATE of ACE/ARBs
on 1-year patient survival to be lower than the upper limit
RCT estimates (50 lives saved per 1,000 high-risk patients).
Our LATE estimates using various local area sizes are all
less than this upper limit. Our LATE estimates are best used
to assess whether higher rates of ACE/ARB prescribing
post-AMI will increase survival rates. If the IV assumptions
hold, our results do not provide clear evidence that higher
treatment rates will increase survival rates. Although our
local practice styleebased instrument described a substan-
tial portion of treatment variation across local area sizes
and, for the most part, treatment effect estimates were pos-
itive, large treatment effect standard errors preclude the re-
jection of the null hypothesis that no survival benefits are
available from higher ACE/ARB prescribing rates. Our re-
sults suggest that providers may be correctly sorting ACE/
ARB treatments to AMI patients in practice and that in-
creasing the ACE/ARB treatment rate beyond 50% may
do little to improve survival rates. However, care should
be taken not to generalize these results to all AMI patients
especially those patients who receive ACE/ARBs in current
practice.Appendix A
To assess the properties of our local area practice style
measures with regard to local area size, we derive a model
of local practice style model based on geographic variation
in provider treatment effectiveness beliefs. Similar results
can be found using other local area factors as the source
S77J.M. Brooks et al. / Journal of Clinical Epidemiology 66 (2013) S69eS83of practice style differences such as variation in the value of
treatment outcomes across areas [31]. Let expected patient
outcome be described by the following model:Yi5b0 þ ½ðb10 þ b1SSiÞ$PN $TiN þ b2Xi þ b2EN þ qiN ; A1
where Yi is the outcome for patient ‘‘i.’’ N designates the
size of the geographic area around patient ‘‘i’’ as defined
by the shortest driving distance required to locate the N
nearest patients with the same clinical condition. TiN is
the treatment choice for patient ‘‘i’’ living in the N-sized
area. ½ðb10 þ b1SSiÞ$PN  represents the range of treatment
effectiveness beliefs across patients with characteristics Si
living in the N-sized area. Under this specification, treat-
ment effectiveness is heterogeneous across patients based
on Si. If Si is characterized in a manner so that higher values
of Si increase treatment effectiveness b1S will be positive.
PN represents average provider treatment effectiveness be-
liefs in N-sized area. The larger PN the more effective the
providers in the area believe treatment is across the range
of Si. EN is the ecological factor in the N-sized area that af-
fect patient outcomes. Xi represents the measured character-
istics for patient ‘‘i’’ that affect the outcome directly,
whereas qiN represents the accumulated unmeasured char-
acteristics of patient ‘‘i’’ living in the N-sized area that af-
fect outcome.
Furthermore, describe treatment choice for patient ‘‘i’’
living in the N-sized area as:TiN5a0 þ a1Xi þ a2Si þ a3PN þ mi A2
where TiN, Xi, PN, and Si are defined as aforementioned.
Under essential heterogeneity, Si is specified in (A2) be-
cause providers are assumed to (1) assess Si for each pa-
tient; (2) have knowledge of the effect of Si on treatment
effectiveness; and (3) recommend treatment choice based
on the value of Si for each patient. Higher Si values increase
treatment effectiveness so a2 in (A2) will be positive. If PN
is measured so that larger PN represents stronger treatment
effectiveness beliefs, a3 will also be positive. Xi has no di-
rect relationship with treatment effectiveness in (A1) so the
theoretical justification for specifying Xi in the treatment
choice equation is unclear. However, we include Xi in
(A2) to remain consistent with general convention. mi
equals the accumulated unmeasured characteristics for pa-
tient ‘‘i’’ that affect treatment choice but do not affect
outcome.If was able to be measured directly, PN could serve as
a valid instrument under the following conditions (1)
a3s 0; (2) Corr(PN, EN) 5 0; (3) Corr(PN, Si) 5 0; and
(4) Corr(PN, qiN) 5 0. Under these conditions, IV estima-
tion will yield a consistent estimate of the LATE of Ti on
Yi  b1PN , that is specific to the distribution of Si values
for the subset of patient whose treatment choices were af-
fected by PN. b1PN will likely represent patients with mod-
erate Si values as patients with very high Si values will
likely receive treatment regardless of PN and patients with
very low Si values will likely not receive treatment regard-
less of PN.
In this article, we measure PN using ATRs for the local
area around each patient residence ZIP code of size N. TiN,
Yi, and Xi are observed by the researcher. We assume Si is
not correlated with the underlying PN and is distributed
evenly across patients with a mean of mS and variance s
2
S.
However, our ATR approach to measure local treatment
preferences for areas of size N solves to the following:ATRN5
PN
i51Ti
.
N
PN
i51
bT i
.
N
5
a0 þ a1XN þ a2SN þPN þ m
ba0 þ ba1X
A3where bT i equals the predicted probability of treatment for
patient ‘‘i’’ conditional on Xi alone. SN equals the mean
of Si in the local area of size N. Local areas, out of chance,
with a larger SN will have more patients apt to gain from
treatment and more patients choosing treatment conditional
on Xi. As a result, our ATRN measure will vary with both PN
and SN . Therefore, when ATRN is used as an instrument re-
placing PN in the empirical model of (A2) in the first stage
of 2SLS, we expect that the ATRN value associated with
each local area will be positively correlated with the un-
measured Si values for the patients within each local area.
This positive correlation will result in an IV estimate of
b1PN that is biased high relative to the true LATE for the
subset of patients whose treatment choices were affected
by PN. However, SN is distributed with mean mS and vari-
ance s2S
.
N. Therefore, as N increases, the variance in SN
across local areas will diminish and a larger portion of
the treatment variation described by ATRN will be gener-
ated from variation in PN, and, all else equal, the positive
bias associated with estimates of b1PNwill diminish.
Appendix B.
Variable Definition/source Source of data Values
Patient demographics
Age Categories were 66e70, 71e75, 76e80, 81e85, more than 85 Beneficiary summary
files (2007e8)
1 if in age category,
0 otherwise
Gender Categories were M, F Beneficiary summary
files (2007e8)
1 if male, 0 female
Race Categories were unknown, white, black, other, Asian, Hispanic, Native American Beneficiary summary
files (2007e8)
1 if in race category,
0 otherwise
Metro/nonmetro
geographic location
Used ruraleurban continuum codes 1e9 developed by the USDA ERS: summarized to metro (1e3) and
nonmetro (4e9) areas
Beneficiary summary
files (2007e8)
1 if in location
category,
0 otherwise
Baseline medical history/comorbidities
Time period Two sets of variables measured: (1) up to 365 days before admission and (2) during admission
AMI At least one inpatient claim with DX codes 410.01, 410.11, 410.21, 410.31, 410.41, 410.51,
410.61, 410.71, 410.81, 410.91 (only first or second DX on the claim) [63]
Part A (inpatient) 1 if code occurs,
0 otherwise
Stroke At least one inpatient claim or two HOP or carrier claims with DX codes 430, 431, 434.00, 434.01,
434.10, 434.11, 434.90, 434.91, 435.0, 435.1, 435.3, 435.8, 435.9, 436, 997.02 (any DX on
the claim); if any of the qualifying claims have 800  DX code  804.9, 850  DX code  854.1 in
any DX position or DX V57xx as the principal DX code, then exclude [63], exclude 435.X per
Ref. [74]
Part A (inpatient), part
B (outpatient, carrier)
X
TIA ICD-9 codes 435.x in hospitalization or emergency encounter data [74] Part A/B X
Heart failure DX 398.91, 402.01, 402.11, 402.91, 404.01, 404.11, 404.91, 404.03, 404.13, 404.93, 428.0,
428.1, 428.20, 428.21, 428.22, 428.23, 428.30, 428.31, 428.32, 428.33, 428.40, 428.41,
428.42, 428.43, 428.9 (any DX on the claim); at least one inpatient, HOP or carrier claim with DX
codes [63]
Part A (inpatient), part
B (outpatient, carrier)
X
AF DX 427.31 (only first or second DX on the claim); at least one inpatient claim or two HOP or carrier
claims with DX code [63]
Part A (inpatient), part
B (outpatient, carrier)
X
PVD DX 443.9, 441.x, 785.4, V43.4; Proc 38.48 [59] Part A/B X
CKD DX 016.00, 016.01, 016.02, 016.03, 016.04, 016.05, 016.06, 095.4, 189.0, 189.9, 223.0,
236.91, 249.40, 249.41, 250.40, 250.41, 250.42, 250.43, 271.4, 274.10, 283.11, 403.01,
403.11, 403.91, 404.02, 404.03, 404.12, 404.13, 404.92, 404.93, 440.1, 442.1, 572.4,
580.0, 580.4, 580.81, 580.89, 580.9, 581.0, 581.1, 581.2, 581.3, 581.81, 581.89, 581.9,
582.0, 582.1, 582.2, 582.4, 582.81, 582.89, 582.9, 583.0, 583.1, 583.2, 583.4, 583.6,
583.7, 583.81, 583.89, 583.9, 584.5, 584.6, 584.7, 584.8, 584.9, 585, 585.1, 585.2, 585.3,
585.4, 585.5, 585.6, 585.9, 586, 587, 588.0, 588.1, 588.81, 588.89, 588.9, 591, 753.12,
753.13, 753.14, 753.15, 753.16, 753.17, 753.19, 753.20, 753.21, 753.22, 753.23, 753.29,
794.4 (any DX on the claim); at least one inpatient, SNF, or HHA claim or two HOP or carrier claims
with DX codes [63]
Part A (inpatient, SNF,
HHA), part B
(outpatient, carrier)
X
Diabetes DX 249.00, 249.01, 249.10, 249.11, 249.20, 249.21, 249.30, 249.31, 249.40, 249.41, 249.50,
249.51, 249.60, 249.61, 249.70, 249.71, 249.80, 249.81, 249.90, 249.91, 250.00, 250.01,
250.02, 250.03, 250.10, 250.11, 250.12, 250.13, 250.20, 250.21, 250.22, 250.23, 250.30,
250.31, 250.32, 250.33, 250.40, 250.41, 250.42, 250.43, 250.50, 250.51, 250.52, 250.53,
250.60, 250.61, 250.62, 250.63, 250.70, 250.71, 250.72, 250.73, 250.80, 250.81, 250.82,
250.83, 250.90, 250.91, 250.92, 250.93, 357.2, 362.01, 362.02, 366.41 (any DX on the
claim); at least one inpatient, SNF, or HHA claim or two HOP or carrier claims with DX codes [63]
AND add a dummy for insulin use from pharmacy claims
Part A (inpatient, SNF,
HHA), part B
(outpatient, carrier),
Part D
X
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Hypertension
(complicated)
DX 402.10, 402.90, 404.10, 404.90, 405.1, 405.9 [65] Part A/B X
Hypertension
(uncomplicated)
DX 401.1, 401.9 [65] Part A/B X
Hyperlipidemia DX 272.xx or a pharmacy claim for a lipid-lowering medication [72] Part A/B/D X
COPD DX 491.0, 491.1, 491.20, 491.21, 491.22, 491.8, 491.9, 492.0, 492.8, 494.0, 494.1, 496 (any
DX on the claim) [63]
Part A/B X
Cancer (general) DX 140.xe172.x, 174.xe195.8, 200.xe208.x [59] Part A/B X
Metastatic cancer DX 196.xe199.x [65] Part A/B X
Asthma DX 493.0, 493.1, 493.9 [61] Part A/B X
Non-AMI ischemic heart
disease (AMI codes
removed)
DX 410.00, 410.02, 410.10, 410.12, 410.20, 410.22, 410.30, 410.32, 410.40, 410.42, 410.50,
410.52, 410.60, 410.62, 410.70, 410.72, 410.80, 410.82, 410.90, 410.92, 411.0, 411.1,
411.81, 411.89, 412, 413.0, 413.1, 413.9, 414.00, 414.01, 414.02, 414.03, 414.04,
414.05, 414.06, 414.07, 414.10, 414.11, 414.12, 414.19, 414.2, 414.3, 414.8, 414.9 Proc
00.66, 36.01, 36.02, 36.03, 36.04, 36.05, 36.06, 36.07, 36.09, 36.10, 36.11, 36.12, 36.13,
36.14, 36.15, 36.16, 36.17, 36.19, 36.2, 36.31, 36.32 HCPCS 33510, 33511, 33512, 33513,
33514, 33516, 33517, 33518, 33519, 33521, 33522, 33523, 33533, 33534, 33535, 33536,
33542, 33545, 33548, 92975, 92977, 92980, 92982, 92995, 33140, 33141 (any DX, PROC,
or HCPCS on the claim); at least one inpatient, SNF, HHA, HOP, or carrier claim with DX, procedure,
or HCPC codes [63]
Part A (inpatient, SNF,
HHA), part B
(outpatient, carrier)
X
CABG ICD-9 procedure codes 36.0e36.39 [67] or CPT 33510e33536 [71] Part A/B X
Stent Stent alone CPT codes 92,980e92,981 [71]; ICD-9-CM procedure code 36.06, drug-eluting stent
(ICD-9-CM procedure code 36.07), or both [73]
Part A/B X
PCI Angioplasty only: ICD-9 procedure codes 36.01, 36.02, 36.05, 36.06 [67] Part A/B X
Charlson Comorbidity
Index
[59] Part A/B 0e19 points
possible
Baseline and postdischarge medications
Time period 180 days before index admission date
Drug classes All drug classes identified by linking part D claims to Multum Lexicon Plus data set (Copyright 2012
Lexi-Comp, Inc. and/or Cenner Multum, Inc.)
Nitrates Part D 1 if prescription
filled during time
period,
0 otherwise
Clopidogrel X Part D X
ACE inhibitors X Part D X
ARBs X Part D X
Beta blockers X Part D X
Lipid-lowering agents X Part D X
Calcium channel
blockers
X Part D X
Warfarin X Part D X
Diuretics (loop
diuretics, thiazide
diuretics,
potassium-sparing
diuretics),
X Part D X
(Continued)
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Appendix B. Continued
Variable Definition/source Source of data Values
Other
antihypertensives
X Part D X
Fenofibrates and other
lipid-lowering agents
X Part D X
Antidiabetics
alphaglucosidase,
amylin analogues,
biguanides,
dipeptidyl
peptidase-4
inhibitors, glucagon-
like peptide 1
receptor agonists,
insulin,
meglitinides,
sulfonylureas,
thiazolidinediones,
others (epalrestat,
exenatide,
glybuzole)
X Part D X
Diagnosis on admission
Anterior wall AMI DX 410.0; 410.1 [66] Part A/B 1 if code occurs,
0 otherwise
Subendocardial
infarction (NSTEMI)
DX 410.7x [66] Part A/B X
Stroke At least one inpatient claim or two HOP or carrier claims with DX codes 430, 431, 434.00, 434.01,
434.10, 434.11, 434.90, 434.91, 435.0, 435.1, 435.3, 435.8, 435.9, 436, 997.02 (any DX on
the claim); if any of the qualifying claims have 800  DX code  804.9, 850  DX code  854.1 in
any DX position OR DX V57xx as the principal DX code, then exclude [63]dexclude TIA codes below
if separating
Part A/B X
Any others? Other AMI locations DX 410.5e410.6, 410.8e410.9 [66] Part A/B X
Complications during admission
Cardiac arrest 427.5 [60] Part A/B 1 if code occurs,
0 otherwise
Ventricular arrhythmia DX 427.1, 427.4, 427.41, 427.42 [70] Part A/B X
Heart failure DX 398.91, 402.01, 402.11, 402.91, 404.01, 404.11, 404.91, 404.03, 404.13, 404.93, 428.0,
428.1, 428.20, 428.21, 428.22, 428.23, 428.30, 428.31, 428.32, 428.33, 428.40, 428.41,
428.42, 428.43, 428.9 (any DX on the claim); at least one inpatient, HOP, or carrier claim with DX
codes [63]
Part A (inpatient), part
B (outpatient, carrier)
X
Cardiogenic shock DX 785.51 [60] Part A/B X
Hypotension DX458.x [79] or DX 458.0 [80] and DX 458.9, 785.5x, and 998.0 [78] Part A/B X
Renal failure Acute renal failure/acute tubular necrosis (DX 584.xx) or acute glomerulonephritis (DX 580.xx) [64,68] Part A/B X
Sepsis DX 995.91 [74] Part A/B X
Pneumonia Secondary DX 481e483 [77] Part A/B X
Procedures during hospitalization
CABG ICD-9 procedure codes 36.0e36.39 [67] and CPT 33510e33536 [71] Part A/B 1 if code occurs,
0 otherwise
Stent ICD-9-CM procedure code 36.06), drug-eluting stent (ICD-9-CM procedure code 36.07) [73] Part A/B X
S
8
0
J.M
.
B
ro
o
ks
et
a
l.
/
Jo
u
rn
a
l
o
f
C
lin
ica
l
E
p
id
em
io
log
y
6
6
(2
0
1
3
)
S
6
9e
S
8
3
PCI Angioplasty only: ICD-9 procedure codes 36.01, 36.02, 36.05, 36.06 [67] Part A/B X
Stress test DX 89.4x, CPT 93015 or CPT codes 93,015e93,018, 93,350, 78,460e78,465, 78,472e78,483,
78,494, 78,496, 78,491e78,492 (includes nuclear imaging) [71]
Part A/B X
Cardiac catheterization CPT codes 93,508, 93,510e93,529, 93,539e93,540, 93,543, 93,545e93,552 [71] Part A/B X
Echocardiography On inpatient claim, ICD-9 procedure code 88.72; on outpatient claim, CPT 93307, 93320, 93325,
93308 [75]
Part A (inpatient),
part B (outpatient)
X
VAD CPT 36533 and 36,489 [76] or ICD-9 procedure codes 37.62, 37.65, and 37.66 [69] Part A/B X
Pacemaker implantation ICD-9 procedure codes 37.80e37.89 [62] Part A/B X
Insurance variables
Entered coverage gap
(Y/N) or number of
months in coverage
gap, patient OOP cost,
*percent of drug class
covered on plan’s
formulary, *patient
OOP cost of
alternatives *Only
available if CMS allows
release of formulary
finder file for the Part D
data
Quartiles for beneficiary responsibility amount, total cost, and plan premium. Deductible phase
separated into one of four categories: pre_ICL_phase, ICL_phase, catastrophic_phase, and
unknown_phase
Part A/B/D 1 if in each category,
0 otherwise
Socioeconomic status variables
Percent below poverty,
high school graduation
rate, per capita
income, percent
English speaking
All variables created as 1/0 based on whether the patient lived in a ZIP code area that was in the upper
or lower 50th percentile for each value
2000 US Census 1 if above median, 0
otherwise
Abbreviations: M, male; F, female; USDA, United States Department of Agriculture; ERS, Economic Research Service; AMI, acute myocardial infarction; DX, diagnosis; PROC, procedure;
HOP, hospital outpatient; TIA, transient ischemic attack; ICD-9, International Classification of Diseases, Ninth Revision; AF, atrial fibrillation; PVD, peripheral vascular disease; CKD, chronic
kidney disease; SNF, skilled nursing facility; HHA, Home Health Agency; COPD, chronic obstructive pulmonary disease; HCPCS, Healthcare Common Procedure Coding System; CABG, coronary
artery bypass graft; CPT, Current Procedural Terminology; ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification; PCI, percutaneous coronary intervention; ACE,
angiotensin converting enzyme; ARBs, angiotensin receptor blocker; NSTEMI, non-ST elevation myocardial infarction; VAD, ventricular assist device; OOP, out of pocket.
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